MacuLogix’s assets sold to Seattle medical device company

The assets of central Pennsylvania-based MacuLogix, a leader in the early diagnosis of dry age-related macular degeneration and developer of the wearable AdaptDX Pro dark adaptometer, were acquired by a wholly owned subsidiary of LumiThera Inc.

Based in Seattle, LumiThera is a commercial-stage medical device company offering photobiomodulation treatment for ocular damage and disease.

MacuLogix is winding down its operations, BizNewsPA reported. Its AdaptDX Pro device allows eye care professionals to measure dark adaptation, which is used to diagnose dry age-related macular degeneration in patients – a leading cause of vision loss for patients 65 and older – earlier than any other technology. It was launched in 2020 and is available for sale in the U.S., Canada, European Union and elsewhere.

“The core technology measures the inability to visually adapt to low levels of light, a key clinical marker seen in patients with early AMD,” Greg Jackson, former MacuLogix chief technology officer and co-founder, said in a release. “Dark adaptation technology has been validated in 42 peer-reviewed papers. Over 1 million AdaptDX tests have been performed and about 200,000 patients have been newly diagnosed.”

Clark E. Tedford, LumiThera’s president and CEO, added: “AdaptDx Pro can identify dry AMD patients at the earliest timepoint, in advance of pathology, and before vision loss. The AdaptDx wearable, light-based early diagnostic for dry AMD adds a complementary assessment of retinal health to the LumiThera product line, further expanding LumiThera’s synergistic platform of products for eye care professionals. We are excited to combine diagnosis, treatment, and monitoring platforms to provide a complete solution for dry AMD patients.”

Paula Wolf is a freelance writer